Heart failure & cardiomyopathiesGuideline or statement
2024 Update to the 2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure
- Performance measures statement (focused update)
Recommendations
As issued by the authors
- New performance measure
Optimal BP control in HFpEF
- New performance measure
SGLT2 inhibitors for HFrEF
- New performance measure
Guideline-directed medical therapy in hospitalized patients
- New quality measure
SGLT2 inhibitors in HF with mildly reduced EF and HFpEF
- New quality measure
Optimization of guideline-directed medical therapy before intervention for chronic secondary severe mitral regurgitation
- New quality measure
Continuation of guideline-directed medical therapy in HF with improved EF
- New quality measure
Identifying known CVD risks and social determinants of health
- New quality measure
Patient-centered counseling on contraception and pregnancy risks in cardiomyopathy
- New quality measure
Monoclonal protein screen to exclude light chain amyloidosis when interpreting a bone scintigraphy scan for transthyretin cardiac amyloidosis
Original publication
Summarised from the published abstract; every number is checked against it